Identifying early signs of Parkinson's in Gaucher mutation carriers
Prodromal Parkinsonian Features in GBA1 Mutation Carriers
This study is trying to find early signs of Parkinson's disease in people with a specific genetic mutation to see who might be at higher risk of developing the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | Shaare Zedek Medical Center Academic / other |
| Locations | 1 site (Jerusalem, Please Select...) |
| Trial ID | NCT05253560 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify a sub-population of individuals carrying GBA1 mutations who are at increased risk of developing Parkinson's disease. Participants will undergo a comprehensive evaluation involving various non-invasive tests, including sensory assessments, blood tests, blood pressure measurements, brain ultrasounds, and neurological evaluations. The study will compare the findings of GBA1 mutation carriers with diagnosed Gaucher patients and healthy individuals who do not carry the mutation. The goal is to detect early signs of Parkinson's disease that may appear up to twenty years before diagnosis.
Who should consider this trial
Good fit: Ideal candidates include individuals who are GBA1 mutation carriers and are willing to participate in the study.
Not a fit: Patients who are already diagnosed with Parkinson's disease or have dementia will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to early identification and potential preventive strategies for individuals at risk of developing Parkinson's disease.
How similar studies have performed: While there is ongoing research into the relationship between Gaucher disease and Parkinson's, this specific approach to identifying prodromal signs in mutation carriers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willing to participate Exclusion Criteria: * PD patients * Dementia
Where this trial is running
Jerusalem, Please Select...
- Michal Becker- Cohen — Jerusalem, Please Select..., Israel (Recruiting)
Study contacts
- Principal investigator: Ari Zimran, MD — Shaare Zedek Medical Center
- Study coordinator: Ari Zimran, MD
- Email: azimran@gmail.com
- Phone: +972-509149149
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.